|Day Low/High||20.26 / 21.32|
|52 Wk Low/High||16.56 / 66.95|
Even though sellers knocked prices down in the afternoon, it will take more than that to stop the current rally.
Despite getting sucker-punched, buyers haven't yet been given enough time or opportunity to lose faith and give up.
Movers roundup: Rite Aid downgraded, Nektar drug candidate effective in early study
Nektar Therapeutics sets two-year high as ovarian cancer drug data follows AstraZeneca pact
The average health care fund rose 1.5% in the past week as investors mulled Obama's health care plan.
Nektar Therapeutics shares rise as Morgan Joseph analyst maintains positive outlook
Nektar Therapeutics shares rise as partner receives FDA approval on potential blockbuster
The weakened economy is causing rheumatoid arthritis patients to put off or delay treatment with expensive injectable drugs and pressuring the leading market players.
The Swiss drug maker will acquire the assets for $115 million in cash.
The latest M&A and what it means more broadly; tapping Russia for drug approvals; the next potential insulin play and more.
Shares of the biotech free fall on fears its lead drug candidate may never make it to market.
Latest study data serve as the death knell for the Exubera program, and also send shares of competitor Mannkind lower.
Nektar, CTC Media upgraged; Brady, Pinnacle West, CNA Surety downgraded.
Pfizer's decision to drop inhaled insulin could dim the prospects for competing products.
The company takes a large charge to leave the inhaled insulin product behind, and earnings plunge.
Emergent BioSolutions gains on a $448 million contract for its anthrax vaccine BioThrax.
Sangamo BioSciences climbs on animal study results for an HIV treatment.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.